אינטגרילין 2 מגמל

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

EPTIFIBATIDE

Disponible desde:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

Código ATC:

B01AC16

formulario farmacéutico:

תמיסה להזרקה

Composición:

EPTIFIBATIDE 2 MG/ML

Vía de administración:

תוך-ורידי

tipo de receta:

מרשם נדרש

Fabricado por:

SCHERING-PLOUGH LABO. N.V , BELGIUM

Grupo terapéutico:

EPTIFIBATIDE

Área terapéutica:

EPTIFIBATIDE

indicaciones terapéuticas:

Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.

Fecha de autorización:

2013-10-31